Allogene Therapeutics
ALLO
168 hedge funds and large institutions have $686M invested in Allogene Therapeutics in 2022 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 67 increasing their positions, 55 reducing their positions, and 41 closing their positions.
55% more call options, than puts
Call options by funds: $621K | Put options by funds: $400K
22% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 55
3.4% more ownership
Funds ownership: 73.91% → 77.31% (+3.4%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
13% less funds holding
Funds holding: 192 → 168 (-24)
40% less capital invested
Capital invested by funds: $1.15B → $686M (-$461M)
51% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 41
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$23M |
| 2 |
Millennium Management
New York
|
+$17.4M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
+$8.66M |
| 4 |
Two Sigma Investments
New York
|
+$7.21M |
| 5 |
Two Sigma Advisers
New York
|
+$6.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$14.9M |
| 2 |
TLP
Tri Locum Partners
New York
|
-$8.47M |
| 3 |
Goldman Sachs
New York
|
-$7.23M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$5.47M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$4.85M |
ALLO Hedge Fund Activity: Q4 2022 in Review
168 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q4 2022, worth a combined $686M — down 40% from $1.15B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of ALLO and 20 opened new positions — a net loss of 21 holders — while 55 trimmed existing stakes and 67 added.
The largest buyer was State Street, adding an estimated $23M. The largest seller was Woodline Partners, cutting an estimated $14.9M.
- 168 institutional investors held Allogene Therapeutics (ALLO) as of Q4 2022, down from 192 in Q3 2022.
- Funds reported $686M of Allogene Therapeutics stock for Q4 2022, down 40% quarter-over-quarter.
- 20 funds opened new Allogene Therapeutics positions in Q4 2022 and 41 closed out, a net change of -21 holders.
- The largest Allogene Therapeutics buyer in Q4 2022 was State Street, an estimated $23M added.
- The largest Allogene Therapeutics seller in Q4 2022 was Woodline Partners, an estimated $14.9M sold.
Based on aggregated 13F filings for Q4 2022.